Astellas Pharma Inc. (ALPMF) Comparison with companies in other sectors?

Astellas Pharma Inc. has a share price of 1.79B. You can analyze Astellas Pharma Inc. (ALPMF) competitors across different market sectors through stock heatmaps.

What are ALPMF's NET and operating margins?

Astellas Pharma Inc. (ALPMF) operating margin is around 0.03, and net profit margin is approximately 0.03 as of the latest reports.

In what way does ALPMF's earnings per share (EPS) trend reflect its financial momentum?

Astellas Pharma Inc. (ALPMF) EPS is 0.19 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Astellas Pharma Inc. is 55.05, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Astellas Pharma Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Astellas Pharma Inc. like P/E which is 55.35, P/B which is 1.86, and PEG which is 0.002. Compare them with sector averages to evaluate if the stock is priced fairly.

Astellas Pharma Inc.

ALPMF•PNK

Healthcare

Drug Manufacturers - General

$10.46

$0.00(0.00%)

Astellas Pharma Inc. (ALPMF) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.19

P/E Ratio

55.05

ROE

0.03%

Net Margin

0.03%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$18.74B

Shares OutstandingTotal number of shares issued

$1.79B

Book Value/ShareNet worth per share

$832.33

Revenue/ShareAnnual revenue per share

$1051.83

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.19

Net MarginNet income as percentage of revenue

2.65%

Operating MarginOperating income as percentage of revenue

3.20%

ROEReturn on shareholders' equity

3.27%

ROAReturn on total assets

1.52%

ROCEReturn on capital employed

2.68%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$86.63

Cash/ShareCash and equivalents per share

$120.08

FCF YieldFree cash flow as percentage of market cap

5.71%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$74.10

Dividend YieldAnnual dividend as percentage of stock price

4.81%

Financial Ratios Analysis data is not available for ALPMFFinancial Ratios Analysis details for ALPMF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ALPMFSector Benchmarking details for ALPMF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Astellas Pharma Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Astellas Pharma Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Astellas Pharma Inc.'s unique business strengths and challenges.

Key Financial Metrics for Astellas Pharma Inc.

For Astellas Pharma Inc., essential financial indicators include EPS 0.19, PE 55.05, and ROE 0.03. These key ratios reveal insights into Astellas Pharma Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Astellas Pharma Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Astellas Pharma Inc.

Metrics like Net Margin 2.65% and ROA 1.52% shed light on how well Astellas Pharma Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Astellas Pharma Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Astellas Pharma Inc.

Using ratios such as P/B Ratio 1.86 and PEG Ratio 0.002, investors can assess whether Astellas Pharma Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Astellas Pharma Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Astellas Pharma Inc.

Financial health indicators, such as Debt/Equity Ratio 0.55 and Cash Flow $86.63, provide a snapshot of Astellas Pharma Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Astellas Pharma Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Astellas Pharma Inc.

Investing in Astellas Pharma Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Astellas Pharma Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;